Compare MakeMyTrip Ltd (MMYT) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MakeMyTrip Ltd vs Moderna, Inc. — how do they compare? MakeMyTrip Ltd trades at $49.2 (market cap $5.07B), while Moderna, Inc. trades at $135.95 (market cap $56.02B). The key difference: Moderna, Inc. is far larger — about 11× MakeMyTrip Ltd's market cap, and Moderna, Inc. is trading nearer its 52-week high, MakeMyTrip Ltd nearer its low. Which is the better fit depends on your goals.
| MMYT | MRNA | |
|---|---|---|
Market Cap | $5.07B | $56.02B |
Sector | Technology | Health |
52-Week High | $101.86 | $174.38 |
52-Week Low | $36.30 | $22.36 |
Enterprise Value | $5.73B | $52.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MakeMyTrip (MMYT) trades at $53.90, down 3.09% today, showing technical bearish signals despite strong analyst support with 8 buy ratings. The company maintains solid revenue growth with $978M in 2025 revenue and $95M net income, though earnings volatility persists with mixed quarterly results. Recent news highlights institutional selling pressure despite positive industry outlook for internet delivery services.
Investment outlook remains cautiously optimistic given the 34% upside potential from analyst targets, but risks include declining cash flow trends and rising debt-to-asset ratios from 12% to 80% projected for 2026. The stock's high P/E ratio of 234 requires sustained earnings growth to justify valuation, making execution critical for future performance.
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
